U.S. Distributes 726k COVID-19 Pills and Monoclonal Antibodies
The U.S. HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) today confirmed the continued implementation of the State and Territory-Coordinated Distribution System for COVID-19 related monoclonal antibodies (mAbs) and oral antivirals.
As of January 11, 2022, HHS/ASPR distributed 726,876 doses to U.S. states, territories, and agencies for local allocations.
Of these doses, the oral antiviral Paxlovid (99,960) and Molinupivir (399,920) were distributed.
And the four authorized mAbs, a total of 226,996 were distributed this week.
The HHS published the 'Outpatient administration guide for healthcare providers' on December 29, 2021. These COVID-19 products are being evaluated for effectiveness against the SARS-CoV-2 betacoronavirus variant known as Omicron.
In addition, the U.S. NIH OpenData portal publishes real-time data focused on Omicron.
Additional mAbs news is published on this Precision Vaccinations webpage.